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Abstract
The periampullary region gives rise to two main subtypes of adenocarcinoma that show either
pancreatobiliary or intestinal differentiation. New data demonstrates that the histological subtype
– more so than the anatomical location – is an important independent prognostic factor. This fuels
the discussion about maintaining ampullary cancer as a separate entity.
Junctions between two different types of epithelial lining
do not only give rise to unique types of diseases, but are
also interesting and relevant areas with regards to tumori-
genesis. Typically, carcinomas arising in these areas may
show a differentiation resembling either of the colliding
epithelia (and sometimes a mixture or an intermediate of
both). Especially in larger tumors, this adds to the difficul-
ties in defining the exact anatomical origin of a given
tumor.
The ampulla of Vater is one of these epithelial junctions,
but its tumors have gained considerably less attention,
which is probably due to their relatively low number,
their reduced diagnostic accessibility, and the fact that dif-
ferentiating clinical concepts with regards to neoadjuvant
or adjuvant treatment strategies are lacking so far. Surgical
treatment of ampullary cancer reaches curative rates of
above 50% whereas the treatment of pancreatic cancer
still has a very low cure rate of around 10% [1,2]. In par-
ticular, lymphatic involvement has been described as lim-
iting the curative possibilities [3] and recently different
molecular changes in metastasis associated genes have
been shown in ampullary and pancreatic cancers [4].
Thus, from a clinical point of view, surgeons have found
that ampullary cancer prognosis also depends on other
factors besides resectability, TNM staging, and lymphatic
involvement.
It was first described by Kimura and coworkers in 1994 [5]
that adenocarcinomas of the ampulla, which comprise
90% of all its malignancies, are constituted of two main
histological subtypes, the intestinal and the pancreatobil-
iary subtypes. This can be attributed to the fact that bile
and pancreatic duct epithelia meet the duodenal mucosa.
Over the years several other studies have confirmed the
findings of the original publication. While the intestinal
type is indistinguishable by histological means from its
colonic counterpart, the same is true for the pancreatobil-
iary type when compared to its relatives [6]. Their differ-
ences do not reside only in the histological pattern of the
tumor cell population. There is sufficient data that show
that, despite the common anatomical location, the differ-
ent subtypes are associated with different premalignant
lesions, cell type specific marker and oncogene expres-
sion, modes of tumor spread, and extent of and interac-
tion with the extracellular matrix. In summary: both
subtypes are likely to have very different molecular patho-
geneses.
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The paper by Westgaard and coworkers [7] addresses the
question of whether in resected periampullary cancer
(which includes also very distal bile and pancreatic duct
carcinomas and periampullary duodenal cancers) locali-
sation to one of the four compartments or the histological
subtyping is more relevant. The study is significant in dif-
ferent ways: Firstly it is prospective, thus carrying less bias,
and all consecutive resection specimens have been sub-
jected to a standardized protocol. Secondly, the number
of cases is sufficiently large for the purpose of the study
and, for comparison, the authors additionally resort to a
retrospective collection of almost equal size. Finally the
data convincingly support the power of histological anal-
ysis. They demonstrate that histological subtyping of
(peri)ampullary carcinoma is a significant prognostistic
factor (more so than the plain anatomical location), with
the intestinal type showing a much better prognosis com-
pared to the pancreatobiliary type. This result is clear cut
and important but it comes as no surprise.
It has long been known for adenocarcinomas of other
organ sites (especially the stomach) that intestinal type
adenocarcinoma carries a more favourable prognosis
compared with the other subtypes and, as mentioned
before, retrospective data on ampullary carcinomas have
shown the same. Furthermore, the ductal type adenocarci-
nomas of the pancreas or distal bile ducts show an
extremely poor prognosis that has been attributed to their
disseminating growth pattern, extreme tendency for
perineural sheet invasion, and their inaccessibility for sys-
temic therapeutics, potentially due to their extensive
desmoplastic stromal reaction.
So, where is the true impact of the current study of West-
gaard et al.? It is one more proof that even in the era of
molecular marker definition, solid histological pattern
analysis is able to develop useful and powerful predictive
information. With regards to clinical decision making,
preoperative biopsy gains another function, and the
future planning of the operation may be further influ-
enced (excision range, resection margins). When it comes
to adjuvant and neoadjuvant concepts, the data lend fur-
ther support to linking ampullary carcinoma to the
respective adenocarcinoma types in the adjacent organs
and not treating it as a separate entity due to the presumed
anatomical localisation. Finally, if differentiation matters
more than anatomical location, as proposed by the study,
it further erodes the necessity for an independent TNM-
classification of ampullary carcinoma and joins other
arguments about the difficulty differentiating it from dis-
tal bile duct and pancreatic adenocarcinoma, and the fact
that many patients even lack a defined ampulla.
Certainly there is a lot more work to do: When it comes to
the molecular pathogenesis, the histological subclassifica-
tion is a solid basis to analyse the presumably different
pathogenetic mechanisms especially with regard to the
ampullary location. Extended molecular fingerprint anal-
yses may help to answer the questions of whether the pan-
creatobiliary type of ampullary carcinoma is truly nothing
else but a very distal pancreatic/biliary adenocarcinoma
and whether the intestinal type should be seen as a plain
duodenal cancer. What about the approximately 15 per-
cent of ampullary adenocarcinomas that do not fit in one
of the two categories? With these findings in hand, ques-
tions of etiology, epidemiology, and preventive measures
may be addressed more specifically. Finally based on
these results we have to answer the questions of whether
TNM-classification has to be adjusted and whether amp-
ullary carcinoma should still be seen as a separate entity
in the future.
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